Whitehawk Therapeutics : Corporate Presentation June 2025

Published: 2025-06-04 14:41:04 ET WHWK

Published on 06/04/2025 at 14:41

Corporate Presentation

June 2025

Relaunch as Whitehawk Therapeutics Marks Transition into ADC-Focused Company

mTOR inhibition

Rare cancer indications

Single commercial product

Upon closing, Aadi is now a wholly-owned subsidiary of Kaken

Advanced ADCs

Broad indications with significant patient populations

3-asset portfolio rapidly progressing to clinic

Whitehawk Therapeutics, an ADC Company

Established Tumor

Biology

Clinically validated, broadly overexpressed tumor targets

Significant Patient

Opportunity

High-potential large cancer indications including lung and ovarian

Advanced ADC

Platform Technology

Engineered for minimal off-target toxicity, greater stability & higher

therapeutic index

Rapidly Advancing

to Clinic

All 3 INDs anticipated by mid-2026

Portfolio Leverages Advanced ADC Technology Platform

HWK-007

PTK7 is an oncofetal pseudokinase w/ broad tumor overexpression

Protein Tyrosine Kinase 7 (PTK7)

HWK-016

MUC16 is a glycoprotein overexpressed in cancers of female origin

Mucin 16 (MUC16)

HWK-206

SEZ6 is a CNS protein upregulated in tumors of neuroendocrine origin

Seizure Protein 6 (SEZ6)

CPT113 Platform

CPT113 Platform

O S S O

O O

N N

Advanced ADC architecture based on novel TOPO1 payload & highly stable linker design

O O

O S S O

N N

O O

O O

DXC006 & DXC1002 also use this platform, and are in Ph1 clinical development in China*

Disclaimer

Whitehawk Therapeutics Inc. published this content on June 04, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 04, 2025 at 18:40 UTC.